GL1X · GenesisL1 explorer

UniProt P06756

Integrin alpha-V (P06756)

Integrin alpha-V (UniProt P06756): 74 experimental structures and 1 predicted model on GenesisL1, 15 ligands bound, 357 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.

UniProt
P06756
Protein
Integrin alpha-V
Experimental structures
74
Predicted models
1
Ligands
15
Pockets
357 · 34 records with a druggable one

Structures

75 records of P06756 in the MolNFT archive: 74 experimental, 1 predicted.

EntryTitleMethodChainsLigandsPockets
1U8CA novel adaptation of the integrin PSI domain revealed from its crystal structurex-ray diffractionA——
1U8CA novel adaptation of the integrin psi domain revealed from its crystal structurex-ray diffractionA——
3IJECrystal structure of the complete integrin alhaVbeta3 ectodomain plus an Alpha/beta transmembrane…x-ray diffractionA——
3IJECrystal structure of the complete integrin ALHAVBETA3 ectodomain plus an ALPHA/BETA transmembrane…x-ray diffractionA——
4G1ECrystal structure of integrin alpha V beta 3 with coil-coiled tag.x-ray diffractionA——
4G1ECrystal structure of integrin alpha V beta 3 with coil-coiled tag.x-ray diffractionA——
4G1MRe-refinement of alpha V beta 3 structurex-ray diffractionA——
4G1MRe-refinement of alpha V beta 3 structurex-ray diffractionA——
4MMXIntegrin AlphaVBeta3 ectodomain bound to the tenth domain of Fibronectinx-ray diffractionA——
4MMXIntegrin ALPHAVBETA3 ectodomain bound to the tenth domain of fibronectinx-ray diffractionA——
4MMYIntegrin ALPHAVBETA3 ectodomain bound to the tenth domain of fibronectin with the iakgdwnd motifx-ray diffractionA——
4MMZIntegrin AlphaVBeta3 ectodomain bound to an antagonistic tenth domain of Fibronectinx-ray diffractionA——
4MMZIntegrin ALPHAVBETA3 ectodomain bound to an antagonistic tenth domain of fibronectinx-ray diffractionA——
4O02AlphaVBeta3 integrin in complex with monoclonal antibody FAB fragment.x-ray diffractionA——
4O02ALPHAVBETA3 integrin in complex with monoclonal antibody Fab fragment.x-ray diffractionA——
4UM8Crystal structure of alpha V beta 6x-ray diffractionA, C——
4UM8Crystal structure of alpha V beta 6x-ray diffractionA, C——
4UM9Crystal structure of alpha V beta 6 with peptidex-ray diffractionA, C——
5FFGCrystal structure of integrin alpha V beta 6 headx-ray diffractionANAG, BMA, MAN, CA, SO47 (best 0.82)
5FFGCrystal structure of integrin alpha V beta 6 headx-ray diffractionA——
5FFOIntegrin alpha V beta 6 in complex with pro-TGF-betax-ray diffractionA, ENAG, MAN, BMA, CA—
5FFOIntegrin alpha V beta 6 in complex with pro-TGF-betax-ray diffractionA, E——
5NEMLocalised reconstruction of alpha v beta 6 bound to Foot and Mouth Disease Virus O PanAsia - Pose A.electron microscopyANAG, MAN, CA7 (best 0.81)
5NEMLocalised reconstruction of alpha V beta 6 bound to foot and mouth disease virus O panasia - pose a.electron microscopyANAG, MAN, CA—
5NERLocalised reconstruction of alpha v beta 6 bound to Foot and Mouth Disease Virus O PanAsia - Pose A…electron microscopyANAG, MAN, CA6 (best 0.81)
5NERLocalised reconstruction of alpha V beta 6 bound to foot and mouth disease virus O panasia - pose a…electron microscopyANAG, MAN, CA—
5NETLocalised Reconstruction of Integrin alpha V beta 6 bound to Foot and Mouth Disease Virus O1 Manisa…electron microscopyANAG, MAN, CA7 (best 0.80)
5NETLocalised reconstruction of integrin alpha V beta 6 bound to foot and mouth disease virus O1 manisa…electron microscopyANAG, MAN, CA—
5NEULocalised Reconstruction of Integrin alpha V beta 6 bound to Foot and Mouth Disease Virus O1 Manisa…electron microscopyA—4 (best 0.83)
5NEULocalised reconstruction of integrin alpha V beta 6 bound to foot and mouth disease virus O1 manisa…electron microscopyA——
6AVQThe therapeutic antibody LM609 selectively inhibits ligand binding to human alpha-V beta-3 integrin…electron microscopyA——
6AVRHuman alpha-V beta-3 Integrin (intermediate conformation) in complex with the therapeutic antibody…electron microscopyA—12 (best 0.84)
6AVRHuman alpha-V beta-3 integrin (intermediate conformation) in complex with the therapeutic antibody…electron microscopyA——
6AVUHuman alpha-V beta-3 Integrin (open conformation) in complex with the therapeutic antibody LM609electron microscopyA—14 (best 0.84)
6AVUHuman alpha-V beta-3 integrin (open conformation) in complex with the therapeutic antibody LM609electron microscopyA——
6DJPIntegrin alpha-V beta-8 in complex with the fabs 8B8 and 68electron microscopyANAG—
6MK0Integrin AlphaVBeta3 ectodomain bound to antagonist TDI-4161x-ray diffractionANAG, BMA, MAN, MN, JUY12 (best 0.80)
6MK0Integrin ALPHAVBETA3 ectodomain bound to antagonist tdi-4161x-ray diffractionANAG, BMA, MAN, MN, JUY—
6MSLIntegrin AlphaVBeta3 ectodomain bound to EETI-II 2.5Dx-ray diffractionANAG, BMA, MAN, MN11 (best 0.80)
6MSLIntegrin ALPHAVBETA3 ectodomain bound to eeti-II 2.5Dx-ray diffractionANAG, BMA, MAN, MN—
6MSUIntegrin alphaVBeta3 in complex with EETI-II 2.5Fx-ray diffractionANAG, BMA, MAN, MN15 (best 0.79)
6MSUIntegrin ALPHAVBETA3 in complex with eeti-II 2.5Fx-ray diffractionANAG, BMA, MAN, MN—
6NAJIntegrin AlphaVBeta3 ectodomain bound to Hr10 variant of the 10th domain of Fibronectin.x-ray diffractionANAG, BMA, MN—
6NAJIntegrin ALPHAVBETA3 ectodomain bound to HR10 variant of the 10TH domain of fibronectin.x-ray diffractionANAG, BMA, MN—
6OM1Crystal structure of an atypical integrinx-ray diffractionA, C, E, GNAG, BMA, MAN, CA19 (best 0.85)
6OM1Crystal structure of an atypical integrinx-ray diffractionA, C, E, GNAG, BMA, MAN, CA—
6OM2Crystal structure of atypical integrin alphaV beta8 with proTGF-beta1 ligand peptidex-ray diffractionA, CNAG, BMA, MAN, CA, GLY16 (best 0.80)
6OM2Crystal structure of atypical integrin alphav BETA8 with protgf-BETA1 ligand peptidex-ray diffractionA, CNAG, BMA, MAN, CA—
6UJAIntegrin alpha-v beta-8 in complex with pro-TGF-beta1electron microscopyANAG, BMA, MAN, CA10 (best 0.79)
6UJAIntegrin alpha-V beta-8 in complex with pro-TGF-BETA1electron microscopyANAG, BMA, MAN, CA—
6UJBIntegrin alpha-v beta-8 in complex with the Fabs C6D4 and 11D12v2electron microscopyANAG, BMA, MAN, CA10 (best 0.79)
6UJBIntegrin alpha-V beta-8 in complex with the fabs C6D4 and 11D12V2electron microscopyANAG, BMA, MAN, CA—
6UJCIntegrin alpha-v beta-8 in complex with the Fabs C6-RGD3 and 11D12v2electron microscopyANAG, BMA, MAN, CA11 (best 0.77)
6UJCIntegrin alpha-V beta-8 in complex with the fabs C6-RGD3 and 11D12V2electron microscopyANAG, BMA, MAN, CA—
7Y1TComplex of integrin alphaV/beta8 and L-TGF-beta1 at a ratio of 1:2electron microscopyANAG, BMA, CA11 (best 0.81)
7Y1TComplex of integrin ALPHAV/BETA8 and L-TGF-BETA1 at a ratio of 1:2electron microscopyANAG, BMA, CA—
8IJ5Cryo-EM structure of Integrin AVB3electron microscopyE—12 (best 0.81)
8TCFIntegrin alpha-v beta-8 in complex with minibinder B8_BP_dsulfelectron microscopyANAG, BMA, MAN, CA12 (best 0.81)
8TCGIntegrin alpha-v beta-6 in complex with minibinder B6_BP_dslfelectron microscopyANAG, MAN, CA9 (best 0.82)
8VS6L-TGF-b3/avb8electron microscopyANAG, BMA, MAN, CA8 (best 0.79)

15 records more on the page itself.

Ligands

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · in 38 records
  • MAN · alpha-D-mannopyranose · in 33 records
  • BMA · beta-D-mannopyranose · in 30 records
  • CA · Calcium ion · in 29 records
  • MN · Manganese (II) ion · in 8 records
  • A1LU4 · 2-[(2~{R},5~{R},8~{S},11~{S})-11-(3-carbamimidamidopropyl)-7-methyl-3,6,9,12,15-pentakis(oxidanylidene)-5-(phenylmethyl)-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]ethanoic acid · in 2 records
  • JUY · (2S)-2-[(1,3-benzothiazole-2-carbonyl)amino]-4-{[5-(1, 8-naphthyridin-2-yl)pentanoyl]amino}butanoic acid · in 2 records
  • A1A6A · (2S)-phenyl{(3S)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]pyrrolidin-1-yl}acetic acid · in 1 record
  • A1A6B · (2S)-(2-cyclopropylphenyl){(3R)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]pyrrolidin-1-yl}acetic acid · in 1 record
  • A1A6H · (2S)-{5-fluoro-2-[(2S)-oxan-2-yl]phenyl}{(3R)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]pyrrolidin-1-yl}acetic acid · in 1 record
  • A1A6I · (2S)-{5-fluoro-2-[(6S)-5-oxaspiro[2.5]octan-6-yl]phenyl}{(3R)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]pyrrolidin-1-yl}acetic acid · in 1 record
  • A1AFA · N-(2,4-dichlorobenzoyl)-L-phenylalanine · in 1 record
  • A1LU7 · 2-[(2~{R},5~{R},8~{S},11~{S})-8-(4-azanylbutyl)-11-(3-carbamimidamidopropyl)-3,6,9,12,15-pentakis(oxidanylidene)-5-(phenylmethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]ethanoic acid · in 1 record
  • GLY · Glycine · in 1 record
  • SO4 · Sulfate ion · in 1 record

Experiment against prediction

Elsewhere

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.